Alector, Inc. (ALEC)
| Market Cap | 261.01M |
| Revenue (ttm) | 21.05M |
| Net Income (ttm) | -142.93M |
| Shares Out | 110.36M |
| EPS (ttm) | -1.39 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 172,805 |
| Open | 2.350 |
| Previous Close | 2.350 |
| Day's Range | 2.350 - 2.420 |
| 52-Week Range | 0.973 - 3.400 |
| Beta | 0.58 |
| Analysts | Buy |
| Price Target | 4.83 (+104.23%) |
| Earnings Date | May 4, 2026 |
About ALEC
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer’s disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson’s disease and Lewy body... [Read more]
Financial Performance
In 2025, Alector's revenue was $21.05 million, a decrease of -79.07% compared to the previous year's $100.56 million. Losses were -$142.93 million, 20.1% more than in 2024.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for ALEC stock is "Buy." The 12-month stock price target is $4.83, which is an increase of 104.23% from the latest price.
News
Alector Transcript: TD Cowen 46th Annual Health Care Conference
The ABC platform enables efficient delivery of antibodies, enzymes, and siRNAs to the brain, showing strong preclinical efficacy and safety. Lead programs are advancing toward IND, with phase 1 trials planned to demonstrate rapid amyloid clearance in Alzheimer’s patients using subcutaneous dosing.
Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL137 (ABC-enabled anti-amyloid anti...
Alector to Participate in the TD Cowen 46th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progre...
Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer
SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progre...
Alector Transcript: BofA Securities CNS Therapeutics Virtual Conference 2025
The session highlighted a robust neurodegeneration pipeline leveraging proprietary BBB technology for enhanced brain drug delivery. Key programs include AL137 (anti-amyloid-β antibody) and AL50 (GCase-ERT), with clinical milestones expected from 2025 to 2027. Strong financials support continued development.
Alector to Participate in the Bank of America CNS Therapeutics Conference
SOUTH SAN FRANCISCO, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progre...
ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES, Nov. 26, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alector, Inc. (“A...
Alector Reports Third Quarter 2025 Financial Results and Provides Business Update
Selected lead candidates AL137 for the company's Alector Brain Carrier (ABC)-enabled anti-amyloid beta antibody in Alzheimer's disease, and AL050 for its ABC-enabled GCase enzyme replacement therapy i...
Clinical Failure Halts Alector's Dementia Program, Company Reduces Workforce
On Tuesday, Alector, Inc. (NASDAQ:ALEC) announced results from the Phase 3 INFRONT-3 trial evaluating latozinemab (AL001) for frontotemporal dementia caused by a progranulin gene mutation (FTD- GRN).
Alector Announces Results from its Phase 3 Clinical Trial of Potential FTD-GRN Therapeutic
Treatment did not slow progression of FTD as measured by the clinical co-primary endpoint Treatment did not slow progression of FTD as measured by the clinical co-primary endpoint
Alector shares plunge after dementia drug fails to slow disease progression
Alector said on Tuesday its experimental drug failed to slow the progression of a rare form of dementia in a late-stage trial, prompting the company to end the study and cut nearly half its workforce.
Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progre...
4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals
Among the recent momentum standouts in the biotechnology sector, four stocks have drawn considerable investor attention, entering the top 10th percentile of momentum-ranked stocks based on decisive we...
Alector Transcript: Study Update
The pipeline features late-stage progranulin-elevating antibodies for FTD-GRN and Alzheimer's, with phase 3 data for latozinemab expected in Q4 2025 and a robust preclinical portfolio leveraging ABC technology for brain delivery. ABC-enabled programs show strong preclinical efficacy and safety, with first-in-human studies planned for 2026–2027.
Alector to Host Virtual Research and Development Event Highlighting PGRN Franchise and Brain Carrier Programs
SOUTH SAN FRANCISCO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating ...
Alector Transcript: H.C. Wainwright 27th Annual Global Investment Conference
Late-stage clinical programs for FTD and Alzheimer's are progressing, with a phase 3 FTD readout expected in early Q4 and a phase 2 Alzheimer's trial completing in 2026. The ABC platform underpins a robust early pipeline, and a strategic GSK partnership supports commercialization.
Alector Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
Neurodegenerative diseases remain a major unmet need, with late-stage and preclinical programs advancing for FTD and Alzheimer's. Key phase 3 data for FTD is expected in Q4, and a robust pipeline leverages proprietary BBB technology. Over $300M in cash supports operations through 2027.
Alector Transcript: Cantor Global Healthcare Conference 2025
The conference highlighted a robust pipeline targeting neurodegenerative diseases, with a lead FTD program nearing pivotal phase III data and strong biomarker support. Strategic partnership with GSK and innovative brain delivery platforms position the company for multiple clinical and commercial milestones in the next two years.
Alector to Participate in Upcoming Healthcare Conferences
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating p...
Alector Earnings Call Transcript: Q2 2025
Latozinemab's pivotal phase III trial for FTD-GRN nears data readout, with strong prior biomarker and clinical results and regulatory alignment. Financials remain robust, supporting a diverse neurodegeneration pipeline and late-stage programs into 2027.
Alector Reports Second Quarter 2025 Financial Results and Provides Business Update
On track to report topline data by mid-Q4 2025 from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN, a severe, rare form of dementia with no approved treatments Ongoing Phase 2 ...
Alector to Host Second Quarter and Mid-Year 2025 Earnings Conference Call
Call Scheduled for Thursday, August 7, 2025, at 4:30 p.m. ET/1:30 p.m. PT Call Scheduled for Thursday, August 7, 2025, at 4:30 p.m. ET/1:30 p.m. PT
Alector Provides Executive Leadership Update
-- Neil Berkley, M.B.A., appointed Interim Chief Financial Officer, succeeding Marc Grasso, M.D., effective June 20, 2025 -- SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Alector, In...
Alector Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025
The company is advancing late-stage programs in frontotemporal dementia and Alzheimer's, leveraging unique blood-brain barrier technology and a broad pipeline targeting neurodegenerative diseases. Strategic partnerships and strong financials support clinical and preclinical development.
Alector to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating p...